Evidence map›Paper›PMID 36276313›Full record

ArticleFrontiers in psychiatry2022

Autoimmune antibodies in first-episode psychosis with red flags: A hospital-based case-control study protocol.

Jianjun Wang, Xuan Liu, Jie Lian, Haotao Zheng, Dongbin Cai, Haobin Cai, Dan Zhou, Songjun Lin, Fanxin Kong, Xiude Qin and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jianjun WangDepartment of Neurology and Psychology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Xuan LiuDepartment of Neurology and Psychology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Jie LianDepartment of Neurology and Psychology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Haotao ZhengDepartment of Neurology and Psychology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Dongbin CaiDepartment of Neurology and Psychology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Haobin CaiDepartment of Neurology and Psychology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Dan ZhouThe Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China.
Songjun LinDepartment of Neurology and Psychology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Fanxin KongDepartment of Neurology and Psychology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Xiude QinDepartment of Neurology and Psychology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
Jianqiang BiDepartment of Public Health, Shenzhen Kangning Hospital, Shenzhen Mental Health Center, Shenzhen, China.
Guangzhou University of Chinese Medicine · CNShenzhen Pingle Orthopedic Hospital · CNShenzhen KangNing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Research is increasingly identifying an overlap between psychosis and immunological dysregulation. Certain autoantibodies are being identified in a small but probably relevant subgroup of patients with psychosis. The term "autoimmune psychosis" (AIP) and its corresponding red-flag signs present the opportunity for a new field in psychiatry to promote diagnostic workup and immunomodulating therapy in individual cases. Objectives: The present protocol aims to determine the seroprevalence of autoantibodies in first-episode psychosis (FEPs) using AIP red flag signs, and to explore the frequency of autoantibody subtypes and potential mediating confounders. Methods/design: This is a hospital-based case-control study. All participants will be consecutively selected from the main tertiary psychiatric hospital in Shenzhen City, China. Individuals admitted to the psychiatric ward and diagnosed with FEPs will be enrolled. Based on recent consensus, participants with red flags of AIPs will be defined as cases, while the remainder will be matched as controls. Seropositive antibodies will be detected and verified in cerebrospinal fluid (CSF) samples based on the fixed cell-based assay (CBA) method. The propensity score-adjusted odds ratios will be determined to investigate the key mediating confounders regarding autoantibody subtypes and red flag subsets. Discussion: The results of this study will facilitate the early identification of AIPs in FEP patients using the red flag sign and help identify key mediators that improve the accuracy of diagnostic algorithms. It will have clinical significance to focus on serum antibodies that have been verified in CSF samples, due to its consistency with clinical practices in current psychiatry.

Indexed as

autoantibodyautoimmunefirst-episode psychosis (FEP)N-methyl-D-aspartate receptors (NMDAR)red flag

Identifiers

PMID36276313
PMCPMC9579361
OpenAlexW4301401334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.